Indivior Announces Q3 2022 Financial Results
Indivior PLC reported its financial results for Q3 2022, indicating continued efforts to address substance use disorders. The company's revenue growth is supported by a robust portfolio of opioid use disorder treatments. It aims to expand into additional chronic conditions and mental health areas. Indivior is dedicated to providing evidence-based treatment on a global scale, with products available in 39 countries. For the period ending September 30, 2022, more detailed information can be found in the earnings release, investor presentation, and webcast available on their official website.
- Revenue growth driven by opioid use disorder treatments.
- Expansion plans into additional chronic conditions.
- Global presence with products in 39 countries.
- None.
SLOUGH, UK and RICHMOND, Va., Oct. 27, 2022 /PRNewswire/ -- Indivior PLC (LON: INDV) today announced its financial results for the period ending September 30, 2022. The earnings release, investor presentation and webcast are available at www.indivior.com.
- The earnings press release can be found at https://www.indivior.com/en/media/press-releases
- The investor presentation can be found at https://www.indivior.com/investors
Indivior will also host a webcast presentation today at 8:00 AM US EST / 13:00 GMT.
The webcast event link is https://edge.media-server.com/mmc/p/23i6t2wv
Participants may also access the presentation telephonically:
Participants may access the presentation telephonically by registering with the following link:
https://register.vevent.com/register/BI7788b990aaff4a54b5aafc49c52d2ad2
Registrants will have an option to be called back immediately prior to the call or be provided a call-in # with a unique pin code following their registration).
About Indivior
Indivior is a global pharmaceutical company working to help change patients' lives by developing medicines to treat substance use disorders (SUD) and serious mental illnesses. Our vision is that all patients around the world will have access to evidence-based treatment for the chronic conditions and co-occurring disorders of SUD. Indivior is dedicated to transforming SUD from a global human crisis to a recognized and treated chronic disease. Building on its global portfolio of opioid use disorder treatments, Indivior has a pipeline of product candidates designed to both expand on its heritage in this category and potentially address other chronic conditions and cooccurring disorders of SUD. Headquartered in the United States in Richmond, VA, Indivior employs more than 900 individuals globally and its portfolio of products is available in 39 countries worldwide. Visit www.indivior.com to learn more. Connect with Indivior on LinkedIn by visiting www.linkedin.com/company/indivior.
View original content to download multimedia:https://www.prnewswire.com/news-releases/indivior-announces-q3-2022-financial-results-301661241.html
SOURCE Indivior
FAQ
What were Indivior PLC's Q3 2022 financial results?
How does Indivior plan to expand its treatments?
Where can I find more information about Indivior's earnings?
In how many countries does Indivior operate?
